Introduction: Sorafenib is the only systemic drug approved for the treatment of advanced
hepatocellular carcinoma (HCC). Within recent years, several investigational agents mainly …

Background: Hepatocellular carcinoma (HCC) remains a significant global health burden
with a high mortality rate. Over the past 40 years, significant progress has been achieved in …

Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its
incidence is on the rise in the developing world. The epidemiology of this cancer is unique …

Hepatocellular carcinoma (HCC) is the sixth most common primary malignancy worldwide,
and the third most common cause of death among cancers worldwide. HCC occurs in …

Summary Background In Western countries, hepatocellular carcinoma (HCC) in hepatitis B
(HBV) patients without cirrhosis was poorly studied. The aim was to describe the …

Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due
to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with …

Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor and a
high impact health problem worldwide. The prevalence of HCC is particularly high in many …

Highlights•The incidence of HCC will continue to rise.•HCC is curable at an early
stage.•New locoregional treatments such as radioembolisation are showing impressive …

Progress in the management of hepatocellular carcinoma (HCC) has been slow and has
limited impact on outcome. Most patients with HCC have two diseases—chronic liver …

Background: Chronic liver disease is a major cause of premature death in sub-Saharan
Africa (sSA). However, due to lack of curative treatment for cirrhosis and hepatocellular …